Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers.
Tommasi C, Pellegrino B, Boggiani D, Sikokis A, Michiara M, Uliana V, Bortesi B, Bonatti F, Mozzoni P, Pinelli S, Squadrilli A, Viani MV, Cassi D, Maglietta G, Meleti M, Musolino A. Tommasi C, et al. Among authors: squadrilli a. Front Oncol. 2021 Sep 6;11:700853. doi: 10.3389/fonc.2021.700853. eCollection 2021. Front Oncol. 2021. PMID: 34552867 Free PMC article. Review.
Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.
Verzè M, Minari R, Gnetti L, Bordi P, Leonetti A, Cosenza A, Ferri L, Majori M, De Filippo M, Buti S, Gasparro D, Nizzoli R, Azzoni C, Bottarelli L, Squadrilli A, Mozzoni P, Tiseo M. Verzè M, et al. Among authors: squadrilli a. Cancers (Basel). 2021 Oct 28;13(21):5403. doi: 10.3390/cancers13215403. Cancers (Basel). 2021. PMID: 34771566 Free PMC article.
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Minari R, Bonatti F, Mazzaschi G, Dodi A, Facchinetti F, Gelsomino F, Cinquegrani G, Squadrilli A, Bordi P, Buti S, Bersanelli M, Leonetti A, Cosenza A, Ferri L, Rapacchi E, Quaini F, Ardizzoni A, Tiseo M. Minari R, et al. Among authors: squadrilli a. Tumori. 2022 Feb;108(1):47-55. doi: 10.1177/03008916211014954. Epub 2021 May 18. Tumori. 2022. PMID: 34002648
High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer.
Negri F, Bozzetti C, Pedrazzi G, Azzoni C, Bottarelli L, Squadrilli A, Lagrasta C, Tamagnini I, Bisagni A, Ragazzi M, Porzio R, Tomasello G, Mori D, Leonardi F, Gnetti L, Crafa P, Sala R, Cascinu S. Negri F, et al. Among authors: squadrilli a. Oncol Rep. 2019 Dec;42(6):2750-2758. doi: 10.3892/or.2019.7349. Epub 2019 Oct 1. Oncol Rep. 2019. PMID: 31578584
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M. Bordi P, et al. Among authors: squadrilli a. Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19. Lung Cancer. 2019. PMID: 31027702 Clinical Trial.
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.
Bersanelli M, Minari R, Bordi P, Gnetti L, Bozzetti C, Squadrilli A, Lagrasta CA, Bottarelli L, Osipova G, Capelletto E, Mor M, Tiseo M. Bersanelli M, et al. Among authors: squadrilli a. J Thorac Oncol. 2016 Oct;11(10):e121-3. doi: 10.1016/j.jtho.2016.05.019. Epub 2016 May 31. J Thorac Oncol. 2016. PMID: 27257132 Free article. No abstract available.
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
Minari R, Bordi P, La Monica S, Squadrilli A, Leonetti A, Bottarelli L, Azzoni C, Lagrasta CAM, Gnetti L, Campanini N, Petronini PG, Alfieri R, Tiseo M. Minari R, et al. Among authors: squadrilli a. J Thorac Oncol. 2018 Jun;13(6):e89-e91. doi: 10.1016/j.jtho.2018.03.013. Epub 2018 Mar 27. J Thorac Oncol. 2018. PMID: 29596911 Free article. No abstract available.
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report.
Minari R, Gnetti L, Lagrasta CA, Squadrilli A, Bordi P, Azzoni C, Bottarelli L, Cosenza A, Ferri L, Caruso G, Silini EM, Tiseo M. Minari R, et al. Among authors: squadrilli a. Transl Lung Cancer Res. 2020 Jun;9(3):787-792. doi: 10.21037/tlcr.2020.04.03. Transl Lung Cancer Res. 2020. PMID: 32676339 Free PMC article.
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Bozzetti C, Nizzoli R, Tiseo M, Squadrilli A, Lagrasta C, Buti S, Gasparro D, Zanoni D, Majori M, De Filippo M, Mazzoni F, Maddau C, Naldi N, Sammarelli G, Frati C, Pinto C, Ardizzoni A. Bozzetti C, et al. Among authors: squadrilli a. Diagn Cytopathol. 2015 Nov;43(11):941-6. doi: 10.1002/dc.23318. Epub 2015 Jul 7. Diagn Cytopathol. 2015. PMID: 26152804
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S, Minari R, Cretella D, Flammini L, Fumarola C, Bonelli M, Cavazzoni A, Digiacomo G, Galetti M, Madeddu D, Falco A, Lagrasta CA, Squadrilli A, Barocelli E, Romanel A, Quaini F, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. Among authors: squadrilli a. J Exp Clin Cancer Res. 2019 May 28;38(1):222. doi: 10.1186/s13046-019-1240-x. J Exp Clin Cancer Res. 2019. PMID: 31138260 Free PMC article.
17 results